Trial Profile
A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (FIGHT-201)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2023
Price :
$35
*
At a glance
- Drugs Pemigatinib (Primary)
- Indications Bladder cancer; Carcinoma; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms FIGHT-201
- Sponsors Incyte Corporation
- 11 Nov 2023 Final Results published in the Annals of Oncology
- 03 Mar 2022 This trial has been completed in Belgium (Date of the global end of the trial : 01-Feb-2022), according to European Clinical Trials Database record.
- 28 Feb 2022 Status changed from active, no longer recruiting to completed.